This is a working overview of MOD GRF 1-29, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-01. Anything still debated is marked as such rather than presented as settled.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
Darren Millar is elected unopposed as leader of the Welsh Conservatives following the resignation of Andrew RT Davies. 6 December – Keir Starmer becomes the third UK prime minister to attend a meeting of the British-Irish Council in 17 years. First Minister of Scotland John Swinney and Prime Minister Keir Starmer hold private talks about the Scottish Government's plans to scrap the two child benefit cap, which are later described as "helpful". Labour MPs Jeevun Sandher and Louise Jones announce their engagement. Dave Penman, general secretary of the FDA union, accuses the prime minister of using "Trumpian language" in his criticism of the civil service. The Labour leader of Bolsover District Council, Steve Fritchley, is cleared over accusations of homophobia. Conservative peer Lord Rami Ranger is stripped of his CBE after a report by the Parliamentary Commission for Standards found he harassed and bullied a journalist via social media. 7 December – Prince William meets US president-elect Donald Trump for talks while visiting France to attend the reopening of Notre-Dame Cathedral. 8 December – Prime Minister Sir Keir Starmer welcomes the Fall of the Assad regime in Syria, which he describes as "barbaric", and calls for the restoration of "peace and stability". Scottish Labour suspends Cammy Day, the leader of Edinburgh City Council, pending the outcome of a police investigation into alleged inappropriate behaviour.
The IAEA conservatively classifies plutonium of all isotopic vectors as "direct-use" material, that is, "nuclear material that can be used for the manufacture of nuclear explosives components without transmutation or further enrichment".
This was part of a larger transition in world views (the rise of the mechanical philosophy) that continued into the 17th century, as the traditional metaphor of nature as organism was replaced by the nature as machine metaphor.
Sources: en.wikipedia.org
Co-dydramol (BAN) is a non-proprietary name used to denote a particular compound analgesic, a combination of dihydrocodeine tartrate and paracetamol. Co-dydramol tablets are used for the relief of moderate pain. Co-dydramol is part of a series of combination drugs available in the UK and other countries including co-codaprin (aspirin and codeine).
By August 2020, when only a few vaccine candidates were in Phase III trials and were many months away from establishing safety and efficacy, numerous governments pre-ordered more than 2 billion doses at a cost of more than US$5 billion. Pre-orders from the British government for 2021 were for five vaccine doses per person, a number dispiriting to organizations like the WHO and GAVI which are promoting fair and equitable access worldwide, especially for developing countries. In September, CEPI was financially supporting basic and clinical research for nine vaccine candidates, with nine more in evaluation, under financing commitments to manufacture 2 billion doses of three licensed vaccines by the end of 2021. Before 2022, 7–10 billion COVID‑19 vaccine doses may be manufactured worldwide, but the sizable pre-orders by affluent countries – called "vaccine nationalism" – threaten vaccine availability for poorer nations. The RNA vaccines from Moderna and Pfizer-BioNTech are unusually difficult to produce because they rely upon encapsulation of mRNA in lipid nanoparticles, a novel technology which has never been scaled up before for mass production. As of February 2021, this was thought to be the primary bottleneck in the manufacturing of such vaccines. In November 2021, Moderna CEO Stéphane Bancel claimed that the company had a backlog of tens of millions of doses of its vaccine destined for Africa because COVAX or individual governments could not take delivery. He cited delays with dose administration, a shortage of refrigerator space, and delays getting customs documents.
== Fabrication == Graphene aerogels are synthetic materials that exhibit high porosity and low density. Typical syntheses of graphene aerogels involve reducing a precursor graphene oxide solution to form graphene hydrogel. The solvent can be subsequently removed from the pores by freeze-drying and replacing with air. The resulting structure consists of a network of covalently bonded graphene sheets surrounding large pockets of air, resulting in densities on the order of 3 mg cm−3. Graphene aerogel morphologies have also been demonstrated to be controllable through 3D printing methods. Graphene oxide ink composed of graphene oxide gelled in a viscous solution with the addition of silica to lower viscosity and enable printability of the graphene oxide ink. The ink is then extruded from a nozzle into isooctane, which prevents the ink from drying too quickly. Subsequently, the solvent can be removed by freeze drying, while the silica can be removed with a hydrofluoric acid solution. The resulting 3D lattice can be highly ordered while maintaining the high surface areas and low densities characteristic of graphene aerogels.
== Early life == On August 13, 1930, Walter David and Addie Turner Mizell welcomed their son Wilmer David into the world. Contrary to popular belief (caused by his nickname), Wilmer was actually born and raised in Leakesville, Mississippi, though the town of Vinegar Bend, Alabama was only a few miles away. His father died when he was two, and his grandmother and uncle brought him up, as his mother was sickly. He grew up laboring on the family farm, which produced fruit and vegetables. The Mizells also raised hogs and cattle. Additional income for Wilmer came from hauling wood, logging, and tapping turpentine from pine trees. "I walked behind more mules than I walked batters – and that's saying a lot," he later reflected, comparing his childhood with his career. Growing up, Mizell was unable to play catch with his brother because he was such an erratic thrower. He practiced his control by throwing at a smokehouse knothole, eventually knocking the door in because of all his practice. At the age of 16, he started playing for baseball teams, pitching in Sunday leagues around Vinegar Bend. The St. Louis Cardinals held a tryout camp in Biloxi, Mississippi, in 1948, and Mizell recorded three strikeouts before a thunderstorm ended it early. Impressed with the youngster, scout Buddy Lewis visited him the following year in Lakeville. Mizell, returning from a local swimming spot, impressed Lewis again with his fastball, and the scout promised to sign him for $500 upon his graduation from Leakeville High School, which would occur later that evening.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.